Dual antiplatelet therapy after intravenous thrombolysis for patients with minor ischemic stroke:A meta-analysis

被引:1
|
作者
Zeng, Jing [1 ]
Xin, Wenli [2 ]
Tang, Shuang [2 ]
Xiang, Chengwei [1 ]
Zeng, Chun [1 ,3 ]
机构
[1] Suining Cent Hosp, Dept Neurosurg, Suining, Sichuan, Peoples R China
[2] Suining Cent Hosp, Dept Cerebrovascular Dis, Suining, Sichuan, Peoples R China
[3] Suining Cent Hosp, Suining, Sichuan, Peoples R China
关键词
Dual antiplatelet therapy; Intravenous thrombolysis; Minor ischemic stroke; Meta-analysis; CLOPIDOGREL PLUS ASPIRIN; ALTEPLASE; TRIAL; SCALE; RISK;
D O I
10.1016/j.clineuro.2024.108176
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Intravenous thrombolysis (IVT) has been shown to effectively decrease both the disability rate and mortality associated with acute ischemic stroke, however, there is also a risk of vascular re -occlusion. Antiplatelet therapy can mitigate this risk. Nevertheless, there are no relevant guidelines recommending whether the administration of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel can be performed following thrombolysis. The aim of this study was to conduct a meta-analysis utilizing multiple studies in order to assess the effectiveness and safety of DAPT after IVT in cases of acute mild ischemic stroke (AMIS). Methods: A comprehensive search on English literature published was performed on databases including PubMed, Embase, Web of Science, and Cochrane up until September 1, 2023. All cases were ischemic stroke patients who underwent IVT within a 4.5 -hour timeframe and had a National Institutes of Health Stroke Scale (NIHSS) score of <= 5 (or 3) upon admission. The primary efficacy endpoint is the 90-day Modified Rankin Scale (mRS) Score (MRS score 0-1), while the primary safety endpoint encompassed the occurrence of symptomatic intracranial hemorrhage (SICH) and 90-day mortality. The study's secondary objective is the recurrence of any type of stroke (hemorrhagic and ischemic) within a 90-day period. The included studies underwent an evaluation of bias risk using the Newcastle Ottawa scale. Risk ratios (RRs) and CIs were calculated using a random effects model, and the findings and heterogeneity among the included studies were visually presented on a forest plot. (There was a protocol registration (PROSPERO):). Results: Out of the 1081 studies that were obtained, only 3 met the criteria and were included in the metaanalysis (657 patients in total). The findings indicate that, there was a significant difference in the mRS of 0-1 between single antiplatelet therapy (SAPT) with only aspirin or clopidogrel and DAPT with aspirin and clopidogrel ((RR,1.11[95%CI,0.99-1.24];P=0.07;I2=55%), and no significant difference in stroke recurrence after 90 days or 1 year ((RR,0.94[95%CI,0.41-2.16];P=0.89;I2=30%); Regarding safety evaluation, the results showed no significant difference in the SICH (RR,0.65[95%CI,0.11-3.97];P=0.64;I2=0%) and the incidence of mortality (RR,0.97[95%CI,0.19-4.96];P=0.97;I2=0%) between the two groups. Conclusions: For patients with acute mild ischemic stroke (AMIS), in conjunction with DAPT after IVT can improve the 90-day prognosis, without increasing the risk of intracranial hemorrhage and 90-day mortality. However, it cannot reduce the risk of stroke recurrence.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Dual versus single antiplatelet therapy in patients with nonminor ischemic stroke: a meta-analysis
    Moro, Izabela Orlandi
    Marinheiro, Gabriel
    Leite, Marianna
    Monteiro, Gabriel de Almeida
    Pinheiro, Agostinho C.
    Telles, Joao Paulo Mota
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2025, 83 (02) : 1 - 10
  • [22] Dual antiplatelet instead of intravenous thrombolysis for minor nondisabling acute ischemic stroke: A perspectivefrom China
    Cui, Yu
    Li, Xiao-Qiu
    Chen, Hui-Sheng
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (01) : 1 - 4
  • [23] Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study Cohort
    Ornello, Raffaele
    Foschi, Matteo
    De Santis, Federico
    Romoli, Michele
    Tassinari, Tiziana
    Saia, Valentina
    Cenciarelli, Silvia
    Bedetti, Chiara
    Padiglioni, Chiara
    Censori, Bruno
    Puglisi, Valentina
    Vinciguerra, Luisa
    Guarino, Maria
    Barone, Valentina
    Zedde, Marialuisa
    Grisendi, Ilaria
    Diomedi, Marina
    Bagnato, Maria Rosaria
    Petruzzellis, Marco
    Mezzapesa, Domenico Maria
    Di Viesti, Pietro
    Inchingolo, Vincenzo
    Cappellari, Manuel
    Zivelonghi, Cecilia
    Candelaresi, Paolo
    Andreone, Vincenzo
    Rinaldi, Giuseppe
    Bavaro, Alessandra
    Cavallini, Anna
    Moraru, Stefan
    Querzani, Pietro
    Terruso, Valeria
    Mannino, Marina
    Pezzini, Alessandro
    Frisullo, Giovanni
    Muscia, Francesco
    Paciaroni, Maurizio
    Mosconi, Maria Giulia
    Zini, Andrea
    Leone, Ruggiero
    Palmieri, Carmela
    Cupini, Letizia Maria
    Marcon, Michela
    Tassi, Rossana
    Sanzaro, Enzo
    Paci, Cristina
    Viticchi, Giovanna
    Orsucci, Daniele
    Falcou, Anne
    Beretta, Simone
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (16):
  • [24] Ticagrelor versus clopidogrel in dual antiplatelet therapy after minor stroke or transient ischemic attack: an updated network meta-analysis
    Marinheiro, Gabriel
    Araujo, Beatriz
    Monteiro, Gabriel de Almeida
    Leite, Marianna
    Mutarelli, Antonio
    de Almeida, Artur Menegaz
    Cavalcante-Neto, Joaquim Francisco
    Rivera, Andre
    Pinheiro, Agostinho C.
    Telles, Joao Paulo Mota
    JOURNAL OF NEUROLOGY, 2024, 271 (06) : 3030 - 3038
  • [25] Antiplatelet Therapy Versus Intravenous Thrombolysis For Mild Nondisabling Acute Ischemic Stroke: A Living Systematic Review And Meta-analysis
    Qin, Mingzhen
    Liu, Tingting
    Shi, Xinyi
    Feng, Luda
    Li, Tingting
    Cheng, Zixin
    Cheng, Sisong
    Zhou, Congren
    Zou, Mingrun
    Jia, Qi
    Zhang, Chi
    Gao, Ying
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44
  • [26] Effect of antiplatelet pretreatment on safety and efficacy outcomes in acute ischemic stroke patients after intravenous thrombolysis: a systematic review and meta-analysis
    Sun, Chao
    Song, Baili
    Jiang, Chunlian
    Zou, Jian-Jun
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (04) : 349 - 358
  • [27] Dual antiplatelet therapy versus intravenous tissue plasminogen activator with acute minor ischemic stroke: A systematic review and meta-analysis of safety and efficacy
    Abbas, Abdallah
    Hamad, Abdullah Ashraf
    Moawad, Mostafa Hossam El Din
    Ewis, Dalia Kamal
    Youssef, Rana Ahmed
    Hamouda, Heba
    Hassan, Malak A.
    Aladawi, Mohammad
    Elfil, Mohamed
    Meshref, Mostafa
    Al -Mufti, Fawaz
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (07):
  • [28] Statin pretreatment combined with intravenous thrombolysis for ischemic stroke patients: A meta-analysis
    Cui, Chaohua
    Li, Qiang
    Li, Changhong
    Zhao, Shubin
    Li, Yuchuan
    JOURNAL OF CLINICAL NEUROSCIENCE, 2022, 98 : 142 - 148
  • [29] Intravenous thrombolysis in ischemic stroke patients with a prior intracranial hemorrhage: a meta-analysis
    Dolatshahi, Mahsa
    Sabahi, Mohammadmandi
    Shahjouei, Shima
    Koza, Eric
    Abedi, Vida
    Zand, Ramin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
  • [30] Intravenous Thrombolysis for Acute Ischemic Stroke in Asia: a Meta-analysis
    Sharma, Vijay K.
    Tsivgoulis, Georgios
    Ng, Kay W.
    Saqqur, Maher
    Venketasubramanian, N.
    Ahmad, Aftab
    Paliwal, Prakash R.
    Yeo, Leonard L.
    Teoh, Hock L.
    Loh, Pei K.
    Ong, Benjamin K.
    Chan, Bernard P.
    STROKE, 2011, 42 (03) : E168 - E168